Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original): A compound of formula (I) or a pharmaceutically acceptable salt thereof:



(I)

wherein:

R^1 represents hydrogen, -C_{1-6} alkyl, -C_{0-4} alkyl-C_{3-8}cycloalkyl, -C_{2-4} alkoxy-C_{1-4} alkyl, -C_{1-4} alkyl-aryl, -C_{1-4} alkyl-heteroaryl or -C_{0-4} alkyl-heterocyclyl, or R^1 is linked to R^2 to form a group $(CH_2)_2$, $(CH_2)_3$ or $(CH_2)_4$;

wherein said alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl groups of R^1 may be optionally substituted by one or more (e.g. 1, 2 or 3) halogen, C_{1-6} alkyl, C_{1-6} alkoxy, cyano, amino or trifluoromethyl groups;

R^2 represents hydrogen or C_{1-6} alkyl;

m represents an integer from 1 to 4, such that when m is an integer greater than 1, two R^2 groups may instead be linked to form a CH_2, $(CH_2)_2$ or $(CH_2)_3$ group;

R^3, R^4 and R^5 independently represent hydrogen, halogen, cyano, -CF_3, -CF_3O, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkanoyl or a group –$CONR^6R^7$;

R^6 and R^7 independently represent hydrogen or C_{1-6} alkyl or R^6 and R^7 together with the nitrogen to which they are attached may form a nitrogen containing heterocyclyl or heteroaryl group;

n represents an integer from 1 to 3;

p represents 1 or 2;

J represents CH_2, CO, CF_2, $CH(OR^8)$, NR^9, SO, O or S;

R^8 and R^9 independently represent hydrogen or C_{1-6} alkyl;

A represents an –aryl, -heteroaryl, -aryl-aryl, -aryl-heteroaryl, -heteroaryl-aryl or –heteroaryl-heteroaryl group;

wherein said aryl and heteroaryl groups of A may be optionally substituted by one or more (e.g. 1, 2 or 3) substituents which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, cyano, nitro, trifluoromethyl, trifluoromethoxy, C_{1-6} alkyl, trifluoromethanesulfonyloxy, pentafluoroethyl, C_{1-6} alkoxy, arylC_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} alkoxyC_{1-6} alkyl, C_{3-7} cycloalkylC_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkoxycarbonyl, C_{1-6} alkylsulfonyl, C_{1-6} alkylsulfinyl, C_{1-6} alkylsulfonyloxy, C_{1-6} alkylsulfonylC_{1-6} alkyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylC_{1-6} alkyl, C_{1-6} alkylsulfonamido, C_{1-6} alkylamido, C_{1-6} alkylsulfonamidoC_{1-6} alkyl, C_{1-6} alkylamidoC_{1-6} alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamidoC_{1-6} alkyl, arylcarboxamidoC_{1-6} alkyl, aroyl, aroylC_{1-6} alkyl, arylC_{1-6} alkanoyl, or a group $CONR^{10}R^{11}$ or $SO_2NR^{10}R^{11}$, wherein R^{10} and R^{11} independently represent hydrogen or C_{1-6} alkyl or R^{10} and R^{11} together with the nitrogen atom to which they are attached may form a nitrogen containing heterocyclyl or heteroaryl group;

or solvates thereof.

2. (Original): A compound of formula (I) as defined in claim 1 which is:

3-[(3-Chlorophenyl)methyl]-8-(1-piperazinyl)quinoline;

(3-Chlorophenyl)[8-(1-piperazinyl)-3-quinolinyl]methanone;

3-(Phenyloxy)-8-(1-piperazinyl)quinoline;

or a pharmaceutically acceptable salt thereof.

3. (Currently amended): A pharmaceutical composition which comprises a compound as defined in claim 1 ~~or claim 2~~ and a pharmaceutically acceptable carrier or excipient.

Claims 4-7 (Cancelled).

8. (Currently amended): A method of treating depression, anxiety, Alzheimer's disease, age related cognitive decline, ADHD, obesity, mild cognitive impairment, schizophrenia, cognitive deficits in schizophrenia and stroke which comprises administering a safe and therapeutically effective amount to a patient in need thereof of a compound of formula (I) as defined in claim 1 ~~or claim 2~~ or a pharmaceutically acceptable salt thereof.